[Comment] Evidence without evolution: a call for precision behavioural therapy in irritable bowel syndrome

In The Lancet Gastroenterology & Hepatology, Elyse Thakur and colleagues1 present an update of their 2020 systematic review and network meta-analysis on the efficacy of behavioural therapies for irritable bowel syndrome (IBS).2 This new meta-analysis, evaluating 67 randomised trials including 7441 participants (of which 26 trials enrolling 3298 patients were newly available since the previous analysis), took a new approach to therapy classification using a framework for brain–gut behaviour therapies.